PDCD1 and esophageal squamous cell carcinoma: This retrospective study found that PD-1 inhibitor-based therapy in real-world ESCC patients led to an ORR of 40.5%, median PFS of 13.6 months, and a low rate of severe TRAEs (3.4%).